CADL Candel Therapeutics, Inc.
As of 3:59 PM ET
- CADL
Loading chart…
- Open
- $5.00
- Previous close
- $5.13
- Day range
- 4.90 – 5.29
- 52-week range
- 4.35 – 14.00
- Volume
- 85.7K
- Avg volume (3M)
- 1.2M
- Market cap
- $417.3M
- P/E (TTM)
- −7.39
- EPS (TTM)
- −$1.53
- Beta
- −0.29
- Dividend yield
- 0.00%
- Next earnings
- Mar 11, 2027(estimated from past report dates; not yet confirmed by the company)
- Ex-dividend
- —
- Sector
- Healthcare
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing viral immunotherapies for cancer. Candel Therapeutics concentrates on off-the-shelf, multimodal biological therapies designed to stimulate anti-tumor immune responses and address solid tumors. Its current pipeline includes CAN-2409, an adenovirus-based program being evaluated in cancers such as prostate, non-small cell lung, and pancreatic cancer, as well as CAN-3110, a herpes simplex virus-based candidate for recurrent high-grade glioma. The company also develops the enLIGHTEN Discovery Platform, which is used to identify and advance new viral immunotherapy candidates. Headquartered in Needham, Massachusetts, Candel Therapeutics plays a specialized role in oncology by combining viral engineering with immunology to support the development of targeted cancer treatments.
Next report: Thu, Mar 11, 2027(estimated from past report dates; not yet confirmed by the company)
| Quarter | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Nov 12, 2026(after close) | −$0.31 | −$0.27 | −12.9% |
| Aug 13, 2026(after close) | −$0.23 | −$0.36 | +56.5% |
| May 14, 2026(after close) | −$0.33 | −$0.14 | −57.6% |
| May 4, 2026(after close) | $0.78 | $0.87 | +11.5% |
| Mar 12, 2026(after close) | −$0.23 | −$0.29 | +26.1% |
CADL doesn’t pay a dividend.
CADL news and filings
Loading filings…
Filings from SEC EDGAR.